药明巨诺-B尾盘涨超21% 5月初至今已翻倍 公司预计下一期间倍诺达的销售收入会再次增加

智通财经
24 Jun

药明巨诺-b(02126)尾盘涨超21%,5月初至今股价已实现翻倍。截至发稿,涨21.37%,报3.18港元,成交额2228.72万港元。消息面上,6月4日,药明巨诺宣布,其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请(NDA)获得中国澳门药物监督管理局批准。公司上月底也曾公布,国家药监局已受理细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10